to Evaluate the Tumor Immune Microenvironment and Clinical Prognosis in Glioma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Apr 23

PMID 33889156

Citations 17

Authors

Shanqiang Qu

Jin Liu

Huafu Wang

Affiliations

Soon will be listed here.

Abstract

Background: Previous research indicated that the tumor cells and microenvironment interactions are critical for the immunotherapeutic response. However, predicting the clinical response to immunotherapy remains a dilemma for clinicians. Hence, this study aimed to investigate the associations between expression and prognosis and tumor-infiltrating immune cells in glioma.

Methods: Firstly, we detected the expression in glioma tissues through biological databases. The chi-squared test, Kaplan-Meier, and univariate and multivariate Cox regression analyses were used to analyze the clinical significance of expression. The correlation between expression and levels of tumor-infiltrating immune cells in glioma tissues was investigated. Receiver operating characteristic (ROC) analysis was performed to compare the predictive power between and other commonly immune-related markers.

Results: In the CGGA cohort of 325 glioma patients, we found that was upregulated in glioma, and increased with tumor grade. High expression was prominently associated with unfavorable clinicopathological features, and poorer survival of patients, which were further confirmed by TCGA (n=609) and GEO (n=74) cohorts. Furthermore, multivariate analysis indicated that is an independent prognostic biomarker for glioma. Importantly, overexpression was associated with a higher infiltration level of CD4 T cells, CD8 T cells, B cells, macrophages, and neutrophils in glioma. ROC curves showed that, compared with , , and , presented a higher area under the curve (AUC) value (AUC=0.824) for predicting high immune infiltration levels in glioma.

Conclusions: We found that was upregulated and could act as a poor prognostic biomarker in glioma. Importantly, overexpression was associated with the immune infiltration levels of immune cells including B cells, CD4 T cells, CD8 T cells, macrophages, and neutrophils, and strongly with the overall immune infiltration levels of glioma. These findings suggested that might be a potential biomarker for evaluating prognosis and immune infiltration in glioma.

Citing Articles

may predict poor prognosis of lower-grade glioma patients and be a potential target for immunotherapy.

Jia Y, Liu M, Liu H, Liang W, Zhu Q, Wang C Cancer Biol Ther. 2024; 25(1):2425134.

PMID: 39555702 PMC: 11581156. DOI: 10.1080/15384047.2024.2425134.

Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of in glioma.

Liu Z, Yang L, Xie Z, Yu H, Gu T, Shi D Oncol Res. 2024; 32(5):965-981.

PMID: 38686055 PMC: 11055992. DOI: 10.32604/or.2024.045769.

Potential diagnostic and drug target markers in glioblastoma.

Ahsan H, Asghar M, Malik S Sci Rep. 2024; 14(1):7292.

PMID: 38538691 PMC: 10973500. DOI: 10.1038/s41598-024-57752-1.

Predictive value of procollagen c-protease enhancer protein on the prognosis of glioma patients.

Yu L, Hu X, Zhu H Heliyon. 2024; 10(6):e28089.

PMID: 38533063 PMC: 10963382. DOI: 10.1016/j.heliyon.2024.e28089.

An integrated analysis of related to malignant properties and immune infiltration of gliomas.

Huang C, Qiu O, Mao C, Hu Z, Qu S Cancer Innov. 2023; 1(3):240-251.

PMID: 38089762 PMC: 10686109. DOI: 10.1002/cai2.29.

References

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R . Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018; 6(1):8. PMC: 5778665. DOI: 10.1186/s40425-018-0316-z. View

Qian Y, Sun H, Xiao H, Ma M, Xiao X, Qu Q . Microarray analysis of differentially expressed genes and their functions in omental visceral adipose tissues of pregnant women with vs. without gestational diabetes mellitus. Biomed Rep. 2017; 6(5):503-512. PMC: 5431681. DOI: 10.3892/br.2017.878. View

Zhen Y, Zhao R, Wang M, Jiang X, Gao F, Fu L . Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer. Theranostics. 2020; 10(18):8080-8097. PMC: 7381743. DOI: 10.7150/thno.43473. View

Chen Y, Chen H, Mao B, Zhou Y, Shi X, Tang L . Transcriptional Characterization Of The Tumor Immune Microenvironment And Its Prognostic Value For Locally Advanced Lung Adenocarcinoma In A Chinese Population. Cancer Manag Res. 2019; 11:9165-9173. PMC: 6827523. DOI: 10.2147/CMAR.S209571. View

Barbee M, Ogunniyi A, Horvat T, Dang T . Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother. 2015; 49(8):907-37. DOI: 10.1177/1060028015586218. View

Wu Z, Tang Y, Niu X, Cheng Q . Expression and gene regulation network of INHBA in Head and neck squamous cell carcinoma based on data mining. Sci Rep. 2019; 9(1):14341. PMC: 6778107. DOI: 10.1038/s41598-019-50865-y. View

Brown S, Warren R, Gibb E, Martin S, Spinelli J, Nelson B . Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014; 24(5):743-50. PMC: 4009604. DOI: 10.1101/gr.165985.113. View

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

Lin B, Wen J, Zheng C, Lin L, Chen C, Qu J . Eva-1 homolog A promotes papillary thyroid cancer progression and epithelial-mesenchymal transition via the Hippo signalling pathway. J Cell Mol Med. 2020; 24(22):13070-13080. PMC: 7701523. DOI: 10.1111/jcmm.15909. View

10.

Shen X, Zhao B . Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018; 362:k3529. PMC: 6129950. DOI: 10.1136/bmj.k3529. View

11.

Ooi Y, Tran P, Ung N, Thill K, Trang A, Fong B . The role of regulatory T-cells in glioma immunology. Clin Neurol Neurosurg. 2014; 119:125-32. DOI: 10.1016/j.clineuro.2013.12.004. View

12.

Tong M, Wang J, He W, Wang Y, Pan H, Li D . Predictive biomarkers for tumor immune checkpoint blockade. Cancer Manag Res. 2018; 10:4501-4507. PMC: 6190817. DOI: 10.2147/CMAR.S179680. View

13.

Vasaikar S, Straub P, Wang J, Zhang B . LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2017; 46(D1):D956-D963. PMC: 5753188. DOI: 10.1093/nar/gkx1090. View

14.

Dong Y, Han Y, Huang Y, Jiang S, Huang Z, Chen R . PD-L1 Is Expressed and Promotes the Expansion of Regulatory T Cells in Acute Myeloid Leukemia. Front Immunol. 2020; 11:1710. PMC: 7412746. DOI: 10.3389/fimmu.2020.01710. View

15.

Zhao Q, Yu J, Meng X . A good start of immunotherapy in esophageal cancer. Cancer Med. 2019; 8(10):4519-4526. PMC: 6712478. DOI: 10.1002/cam4.2336. View

16.

Giunta E, Barra G, De Falco V, Argenziano G, Napolitano S, Vitale P . Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. Sci Rep. 2020; 10(1):17626. PMC: 7573589. DOI: 10.1038/s41598-020-72711-2. View

17.

Zhang X, He T, Li Y, Chen L, Liu H, Wu Y . Dendritic Cell Vaccines in Ovarian Cancer. Front Immunol. 2021; 11:613773. PMC: 7874064. DOI: 10.3389/fimmu.2020.613773. View

18.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

19.

Peng L, Chen Z, Chen Y, Wang X, Tang N . MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Cancer Med. 2019; 8(17):7161-7173. PMC: 6885872. DOI: 10.1002/cam4.2583. View

20.

Pan J, Zhou H, Cooper L, Huang J, Zhu S, Zhao X . LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers. Front Immunol. 2019; 10:6. PMC: 6362421. DOI: 10.3389/fimmu.2019.00006. View